Fulgent Genetics, Inc.

Fulgent Genetics, Inc. is a technology-based company primarily focused on providing comprehensive genetic testing services to deliver clinically actionable diagnostic information. Founded in 2011, the company's mission is to develop flexible and affordable diagnostics and therapeutics to improve patient care. Its headquarters are located in El Monte, California.

The company leverages proprietary technology platforms that integrate sophisticated data comparison algorithms, adaptive learning software, Next-Generation Sequencing (NGS) capabilities, and integrated laboratory processes. Fulgent Genetics offers an extensive test menu, including over 18,000 single-gene tests and numerous multi-gene and disease-specific panels for conditions such as various cancers, cardiovascular diseases, neurological disorders, and pediatric conditions. Additionally, it operates Picture Genetics, a consumer-oriented subsidiary for at-home genetic testing, and has a therapeutic development business focused on creating drug candidates for a broad range of cancers.

Led by founder, Chairman, and CEO Ming Hsieh, Fulgent Genetics has been actively expanding its capabilities. In March 2026, the company completed the acquisition of Bako Diagnostics and StrataDx, enhancing its pathology assets and laboratory footprint. While the first quarter of 2026 saw a modest revenue decline and wider losses, partly due to a major customer transitioning testing in-house, the company maintained its full-year revenue guidance. Fulgent Genetics is also advancing its therapeutic development pipeline, with clinical candidates FID-007 and FID-022, and aims to evolve into a fully integrated precision medicine company.

Latest updates

Fulgent's Q1 Loss Widens Amid Stock Buyback and Pipeline Investment

Event summary

  • Fulgent Genetics reported Q1 2026 revenue of $71.1 million, a decrease from $73.463 million in Q1 2025.
  • The company posted a GAAP loss of $24.8 million, or $(0.80) per share, and a non-GAAP loss of $11.0 million, or $(0.36) per share.
  • Fulgent executed a stock repurchase program, accounting for $48.7 million in cash used and a reduction of 3.1 million shares.
  • The company is updating its Non-GAAP EPS and cash guidance for the year, maintaining its revenue guidance but anticipating margin normalization in the second half.

The big picture

Fulgent's results reflect the broader challenges facing diagnostic testing companies as pandemic-era demand normalizes. The company's strategic shift towards therapeutic development, while promising, requires significant investment and carries inherent risks. The stock repurchase program signals a belief in the company's long-term value, but also underscores the need to manage cash flow effectively amidst ongoing losses.

What we're watching

Margin Pressure
The anticipated margin normalization in the second half of 2026 will need to be closely monitored, as it suggests ongoing pricing or cost challenges within the laboratory services segment.
Pipeline Progress
The presentation of Phase 2 data for FID-007 at ASCO will be a critical inflection point, and the results will significantly influence investor sentiment regarding the therapeutic development pipeline's viability.
IRS Delays
The delayed receipt of approximately $106 million in tax refunds, due to government shutdowns, highlights a dependency on external factors and could impact the company’s cash position and future investment plans.
CID: 3786